Number of Shares and Voting Rights of Adocia as of February 28th, 2022
16 Mars 2022 - 6:00PM
Business Wire
Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French
« Code de Commerce » and article 223-16 of the French stock-market
authorities (Autorité des Marchés Financiers, or “AMF”) charter
ADOCIA SA, a French société anonyme (corporation), 115, avenue
Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC)
(Paris:ADOC) a clinical stage biopharmaceutical company focused on
treatment of diabetes, obesity and metabolic diseases with
innovative formulations of approved proteins, releases its total
number of outstanding shares as well as its voting rights as of
February 28th, 2022.
Month
Date
Total number of outstanding
shares
Total number of theoretical
voting rights (1)
Total number of exercisable
voting rights (2)
February
02/28/2022
7 359 167*
10 146 290
10 099 106
*including 32,277 new shares resulting from the conversion of
210,000 convertible bonds into shares (OC 1023) issued by the
Company on October 26, 2021, the main characteristics of which are
described in its press release of the same day.
(1) The total number of theoretical voting rights (or “gross”
voting rights) is used as the basis for calculating the crossing of
shareholding thresholds. In accordance with Article 223-11 of the
AMF General Regulation, this number is calculated on the basis of
all shares to which voting rights are attached, including shares
whose voting rights have been suspended.
(2) The total number of exercisable voting rights (or” net”
voting rights) is calculated without taking into account the shares
with suspended voting rights, in this case, shares held by the
Company in the context of a liquidity agreement.
About Adocia
Adocia is a clinical-stage biotechnology company that
specializes in the development of innovative formulations of
therapeutic peptides and proteins for the treatment of diabetes and
metabolic diseases. In the diabetes field, Adocia’s portfolio of
injectable treatments is among the largest and most differentiated
of the industry, featuring six clinical-stage products and several
pre-clinical products.
Adocia’s clinical pipeline includes five novel insulin
formulations for the treatment of diabetes: two ultra-rapid
formulations of insulin analog lispro (BioChaperone® Lispro U100
and U200), a combination of basal insulin glargine and rapid acting
insulin lispro (BioChaperone® Combo) and two combinations of a
prandial insulin with amylin analog pramlintide (M1Pram and
BioChaperone® LisPram). The clinical pipeline also includes an
aqueous formulation of human glucagon (BioChaperone® Glucagon) for
the treatment of hypoglycemia.
Adocia’s preclinical pipeline includes bi-hormonal combinations
for diabetes treatment: a combination of aspart rapid acting
insulin analog and pramlintide (BioChaperone® AsPram), a
combination of insulin glargine with GLP-1 receptor agonist
(BioChaperone® Glargine Liraglutide). In addition, there are three
multi-hormonal products for the treatment of obesity: a combination
of glucagon and exenatide (BioChaperone® GluExe), a combination of
pramlintide and exenatide (PramExe) and a triple combination of
pramlintide glucagon exenatide (BioChaperone® PramGluExe).
Adocia's portfolio is based on three technology platforms: 1)
The BioChaperone® platform is designed to enhance the effectiveness
and/or safety of therapeutic proteins while making them easier for
patients to use; 2) A platform designed to improve cell therapy
techniques using a hydrogel matrix; 3) A platform for the oral
delivery of peptides.
Disclaimer
This press release contains certain forward-looking statements
concerning Adocia and its business. Such forward-looking statements
are based on assumptions that Adocia considers as being reasonable.
However, there can be no guarantee that the estimates contained in
such forward-looking statements will be achieved, as such estimates
are subject to numerous risks including those which are set forth
in the “Risk Factors” section of the Universal Registration
Document that was filed with the French Autorité des marchés
financiers on April 20, 2021 (a copy of which is available at
www.adocia.com), in particular uncertainties that are linked to
research and development, future clinical data, analyses, and the
evolution of the economic context, the financial markets and the
markets in which Adocia operates.
The forward-looking statements contained in this press release
are also subject to risks not yet known to Adocia or not considered
as material by Adocia as of this day. The occurrence of all or part
of such risks could cause that actual results, financial
conditions, performances, or achievements of Adocia be materially
different from those mentioned in the forward-looking
statements.
This press release and the information contained herein do not
constitute an offer to sell or the solicitation of an offer to buy
Adocia’s shares in any jurisdiction.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220316005824/en/
Adocia Gérard Soula CEO contactinvestisseurs@adocia.com
Ph: +33 4 72 610 610 www.adocia.com
MC Services AG Adocia Press Relations Europe Raimund Gabriel,
Shaun Brown, Andreas Jungfer adocia@mc-services.eu Ph: +49 89
210 228 0
Adocia (EU:ADOC)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Adocia (EU:ADOC)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
